REPLIMUNE GROUP INC (REPL) — insider trading
Health Care · NASDAQ
REPLIMUNE GROUP INC (REPL) has 24 reported SEC Form 4 insider transactions in our data, including 2 open-market purchases and 12 open-market sales among the most recent 24 (latest 2026-08-20).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-20 | Astley-Sparke Philip | Director | Bona fide gift | 50,000 | — | $0 | Form 4 |
| 2026-08-17 | Hill Emily Luisa | Officer (Chief Financial Officer) | Open-market sale | 9,256 | $14.28 | $132.2K | Form 4 |
| 2026-08-11 | BAKER BROS. ADVISORS LP; Baker Bros. Advisors (GP) LLC; 667, L.P.; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN | Director, 10% owner | Open-market purchase (derivative) | 2,609,946 | $12.06 | $31.48M | Form 4 |
| 2026-08-11 | BAKER BROS. ADVISORS LP; Baker Bros. Advisors (GP) LLC; 667, L.P.; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN | Director, 10% owner | Open-market purchase (derivative) | 126,394 | $12.06 | $1.52M | Form 4 |
| 2026-08-10 | Schwendenman Andrew | Officer (Chief Accounting Officer) | Open-market sale | 7,632 | $12.97 | $99.0K | Form 4 |
| 2026-08-10 | Xynos Konstantinos | Officer (Chief Medical Officer) | Open-market sale | 11,447 | $12.97 | $148.5K | Form 4 |
| 2026-08-10 | Hill Emily Luisa | Officer (Chief Financial Officer) | Open-market sale | 11,448 | $12.97 | $148.5K | Form 4 |
| 2026-08-10 | Patel Sushil | Director, Officer (Chief Executive Officer) | Open-market sale | 39,341 | $12.97 | $510.3K | Form 4 |
| 2026-06-01 | Sarchi Christopher | Officer (Chief Commercial Officer) | Open-market sale | 12,000 | $9.24 | $110.9K | Form 4 |
| 2026-05-18 | Hill Emily Luisa | Officer (Chief Financial Officer) | Open-market sale | 7,812 | $5.08 | $39.7K | Form 4 |
| 2026-05-18 | Patel Sushil | Director, Officer (Chief Executive Officer) | Open-market sale | 37,324 | $5.08 | $189.6K | Form 4 |
| 2026-05-18 | Astley-Sparke Philip | Director | Open-market sale | 17,657 | $5.08 | $89.7K | Form 4 |
| 2026-05-18 | Sarchi Christopher | Officer (Chief Commercial Officer) | Open-market sale | 8,626 | $5.08 | $43.8K | Form 4 |
| 2026-05-18 | Schwendenman Andrew | Officer (Chief Accounting Officer) | Open-market sale | 7,894 | $5.08 | $40.1K | Form 4 |
| 2026-05-18 | Xynos Konstantinos | Officer (Chief Medical Officer) | Open-market sale | 14,023 | $5.08 | $71.2K | Form 4 |
| 2026-04-01 | Xynos Konstantinos | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 75,000 | — | $0 | Form 4 |
| 2026-04-01 | Xynos Konstantinos | Officer (Chief Medical Officer) | Grant / award / vesting | 50,000 | — | $0 | Form 4 |
| 2026-04-01 | Oliger Christy J. | Director | Grant / award / vesting (derivative) | 44,500 | — | $0 | Form 4 |
| 2026-04-01 | Astley-Sparke Philip | Director | Grant / award / vesting (derivative) | 75,000 | — | $0 | Form 4 |
| 2026-04-01 | Astley-Sparke Philip | Director | Grant / award / vesting | 50,000 | — | $0 | Form 4 |
| 2026-04-01 | Sarchi Christopher | Officer (Chief Commercial Officer) | Grant / award / vesting (derivative) | 75,000 | — | $0 | Form 4 |
| 2026-04-01 | Sarchi Christopher | Officer (Chief Commercial Officer) | Grant / award / vesting | 50,000 | — | $0 | Form 4 |
| 2026-04-01 | BAKER BROS. ADVISORS LP; Baker Bros. Advisors (GP) LLC; 667, L.P.; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN | Director, 10% owner | Grant / award / vesting (derivative) | 44,500 | — | $0 | Form 4 |
| 2026-04-01 | BAKER BROS. ADVISORS LP; Baker Bros. Advisors (GP) LLC; 667, L.P.; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN | Director, 10% owner | Grant / award / vesting (derivative) | 44,500 | — | $0 | Form 4 |
Ask the chat about REPL's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: REPLIMUNE GROUP INC (REPL).
Last updated 2026-08-20 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.